Clinical trials: HAP - Hospital Acquired Pneumonia
HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
Multicenter, randomized, controlled, open-label trial to assess if semiquantitative multiplex PCR assay, as compared to conventional microbiology, can reduce the percentage of patients without microbiological diagnosis in the…
- Trial name
- LIGHTNING (NCT05952648)
- Testing
- Lower tract respiratory samples, Multiplex PCR assay (Film-array Pneumonia Panel Plus), Lower respiratory tract standard culture
- Where
- 4 sites in Italy
- Volunteers
- 126 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Critically ill people who need a breathing machine often develop hospital-acquired lung infections. These infections are commonly treated with the antibiotics piperacillin/tazobactam or meropenem.
- Conditions
- Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP), Nosocomial Respiratory Infection, Critical Illness
- Trial name
- ROAD-RCT (NCT07820501)
- Testing
- Resistance-Optimised Precision Dosing, Standard Care Dosing
- Volunteers
- 610 people
- Sponsor
- The University of Queensland
Hospital Acquired Pneumonia (HAP), Cardiovascular and Respiratory Disease
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia
The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between…
- Trial name
- HOMI-LUNG-HAP (NCT06602934)
- Testing
- Blood samples, Oropharyngeal swabs, ECG
- Where
- 5 sites in France
- Volunteers
- 300 people
- Sponsor
- Nantes University Hospital
Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP)
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem.
- Conditions
- Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
- Trial name
- AWARE (NCT07268560)
- Testing
- Aztreonam-Avibactam
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sir Run Run Shaw Hospital
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia…
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Trial name
- APEKS-NP (NCT03032380)
- Testing
- Cefiderocol, Meropenem, Linezolid
- Where
- 119 sites in United States, Belgium and 17 more
- Volunteers
- 300 people
- Sponsor
- Shionogi